Eptinezumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CALCA/CALCB, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. 7 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). 8, 1, 2, 3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.